- Home
- CDXS vs HQL Comparison
CDXS vs HQL Comparison
Compare CDXS & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDXS
- HQL
- Stock Information
- Founded
- CDXS 2002
- HQL 1992
- Country
- CDXS United States
- HQL United States
- Employees
- CDXS N/A
- HQL N/A
- Industry
- CDXS Major Chemicals
- HQL Investment Managers
- Sector
- CDXS Industrials
- HQL Finance
- Exchange
- CDXS Nasdaq
- HQL Nasdaq
- Market Cap
- CDXS 332.0M
- HQL 377.2M
- IPO Year
- CDXS 2010
- HQL N/A
- Fundamental
- Price
- CDXS $4.61
- HQL $13.78
- Analyst Decision
- CDXS Buy
- HQL
- Analyst Count
- CDXS 2
- HQL 0
- Target Price
- CDXS $11.00
- HQL N/A
- AVG Volume (30 Days)
- CDXS 717.6K
- HQL 120.9K
- Earning Date
- CDXS 10-31-2024
- HQL 01-01-0001
- Dividend Yield
- CDXS N/A
- HQL 11.56%
- EPS Growth
- CDXS N/A
- HQL N/A
- EPS
- CDXS N/A
- HQL 0.79
- Revenue
- CDXS $64,446,000.00
- HQL N/A
- Revenue This Year
- CDXS N/A
- HQL N/A
- Revenue Next Year
- CDXS $2.02
- HQL N/A
- P/E Ratio
- CDXS N/A
- HQL $17.08
- Revenue Growth
- CDXS N/A
- HQL N/A
- 52 Week Low
- CDXS $1.85
- HQL $11.34
- 52 Week High
- CDXS $4.91
- HQL $14.37
- Technical
- Relative Strength Index (RSI)
- CDXS 73.88
- HQL 33.14
- Support Level
- CDXS $3.70
- HQL $13.68
- Resistance Level
- CDXS $4.20
- HQL $14.37
- Average True Range (ATR)
- CDXS 0.31
- HQL 0.27
- MACD
- CDXS 0.05
- HQL -0.10
- Stochastic Oscillator
- CDXS 93.50
- HQL 5.92
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.